Psilocybin-facilitated Treatment for Cocaine Use
NCT02037126 · University of Alabama at Birmingham
What it is testing
Summary
Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.
What counts as success
Primary outcome measures
Percentage of Abstinent Days
Measured over From the psilocybin or placebo administration session to end-of-treatment (approximately 4 weeks in most participants), from end-of-treatment to 12 weeks after end-of-treatment, and from 12 weeks after end-of-treatment to 24 weeks after end-of-treatment.
Number of Participants With Complete Abstinence From Cocaine
Measured over From the psilocybin or placebo administration session to 24 weeks after end-of-treatment.
Number of Days to First Use of Cocaine
Measured over From the psilocybin or placebo administration session to 24 weeks after end-of-treatment.
A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.
Who can take part
Eligibility, as published
Where
1 study site
| Facility | City | Region | Country |
|---|---|---|---|
| UAB Outpatient Clinical Research Unit | Birmingham | Alabama | United States |
On the registry
Contact the trial directly
This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.
Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.
NCT02037126 on ClinicalTrials.gov →
Last updated in the registry 2026-05-18. Registry records change; this page reflects the data build of 2026-08-25.
Related
Where this trial sits
Substance
Recruiting in